ACM
PTCT icon

AlphaCrest Capital Management’s PTC Therapeutics PTCT Stock Holding History

AlphaCrest Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-4,416
Closed -$222K – 878
2022
Q3 		$222K Sell
4,416
-4,327
-49% -$212K 0.01% 1220
2022
Q2 		$350K Sell
8,743
-5,747
-40% -$202K 0.02% 1062
2022
Q1 		$541K Sell
14,490
-5,732
-28% -$221K 0.03% 862
2021
Q4 		$805K Sell
20,222
-12,254
-38% -$469K 0.03% 899
2021
Q3 		$1.21M Buy
32,476
+11,790
+57% +$484K 0.06% 530
2021
Q2 		$874K Buy
20,686
+7,989
+63% +$342K 0.04% 729
2021
Q1 		$601K Buy
12,697
+8,806
+226% +$523K 0.03% 719
2020
Q4 		$237K Sell
3,891
-4,213
-52% -$248K 0.02% 1007
2020
Q3 		$379K Buy
8,104
+4,111
+103% +$202K 0.04% 740
2020
Q2 		$203K Buy
+3,993
New +$196K 0.03% 838
2019
Q4 		– Sell
-9,410
Closed -$318K – 1345
2019
Q3 		$318K Buy
+9,410
New +$410K 0.02% 1086

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AlphaCrest Capital Management's PTCT Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of PTC Therapeutics (PTCT) in Q4 2022, closing a stake of 4,416 shares — an estimated $222K sold.

AlphaCrest Capital Management first reported a position in PTCT in Q3 2019 and held it in 11 quarters. The position peaked at $1.21M in Q3 2021. 203 funds tracked by Wall St. Rank hold PTCT as of Q4 2022.

  • AlphaCrest Capital Management reported no remaining PTC Therapeutics position as of Q4 2022 after selling out during the quarter.
  • AlphaCrest Capital Management sold 4,416 PTC Therapeutics shares in Q4 2022, an estimated $222K.
  • AlphaCrest Capital Management first reported a position in PTC Therapeutics in Q3 2019 and held it in 11 quarters.
  • AlphaCrest Capital Management's PTC Therapeutics position peaked at $1.21M in Q3 2021.
  • 203 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.